Clinical trials: Endocrinology
Cardiovascular Diseases, Obesity
Triage Survey for Cardiovascular, Obesity, and Related Endocrine Trial Eligibility
SWIFT-CORE-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials.
- Conditions
- Cardiovascular Diseases, Obesity, PreDiabetes, Diabetes Type 2
- Trial name
- SWIFT-CORE-101 (NCT06412536)
- Testing
- Blood work
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brooklyn Clinical Research
Type 2 Diabetes Mellitus
Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
- Trial name
- T2DM (NCT04100473)
- Testing
- Inhaled Human Insulin, Insulin Lispro (Humalog U-100)
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Dance Biopharm Inc.
Type II Diabetes Mellitus
Effects of a Spiced Meat Patty on Inflammation in Men With Type 2 Diabetes
Polyphenols belong to the largest group of secondary metabolites produced by plants, mainly, in response to biotic or abiotic stresses such as infections, wounding, UV irradiation, exposure to ozone, pollutants, and other hostile…
- Trial name
- NCT01076829
- Testing
- Spice polyphenols
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Kidney Disease, Secondary Hyperparathyroidism
START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary…
- Conditions
- Kidney Disease, Secondary Hyperparathyroidism, Chronic Kidney Disease
- Trial name
- NCT00132431
- Testing
- Sensipar
- Volunteers
- 300 people
- Sponsor
- Amgen
Hypertension, Type 2 Diabetes Mellitus
Amiloride for Resistant Hypertension
To evaluate the antihypertensive effect of amiloride added to triple antihypertensive therapy in patients with resistant hypertension (RH) and type 2 diabetes mellitus (T2DM)
- Conditions
- Hypertension, Type 2 Diabetes Mellitus, Microalbuminuria
- Trial name
- NCT02122731
- Testing
- Amiloride
- Where
- 4 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- Ib Abildgaard Jacobsen
Type 2 Diabetes Mellitus
Real-life Efficacy of Insulia® Tool in Patients Living with Type 2 Diabetes Treated with Basal Insulin Therapy As Part of a National Telemedicine Program (ETAPES)
The purpose of this study was to evaluate the INSULIA digital tool (automation of basal insulin dose calculation in type 2 diabetes) within the framework of a French national telemedicine experimentation program (ETAPES) in a…
- Trial name
- INSULIA (NCT05331339)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Centre Hospitalier Sud Francilien
Type 2 Diabetes, Hyperlipidemias
The Medicines Advice Service Evaluation
The purpose of this study is to find out whether talking to a pharmacist on the telephone can help to support people taking medicine for a long-term condition.
- Trial name
- NCT01864239
- Testing
- Medicines Advice Service
- Where
- United Kingdom
- Volunteers
- 677 people
- Sponsor
- University College, London
Diabetic Foot, Neuropathic Foot Ulcer
Application of S26E for Diabetic Foot Ulcer Healing
A randomized, controlled open-label, parallel group study to examine the effectiveness of a local application of the kalahari melon (Citrullus lanatus) seed oil for the healing of non-infected diabetic foot ulcers.
- Conditions
- Diabetic Foot, Neuropathic Foot Ulcer, Chronic Diabetic Ulcer of Left Foot (Diagnosis), Chronic Diabetic Foot Ulcer of Right Foot
- Trial name
- NCT04186377
- Testing
- Standard-of-care for neuropathic/neuroischemic diabetic foot ulcers, S26E
- Where
- Greece
- Volunteers
- 5 people
- Sponsor
- National and Kapodistrian University of Athens
Gestational Diabetes
An Exercise Intervention to Prevent Gestational Diabetes
Women diagnosed with gestational diabetes mellitus (GDM) are at substantially increased risk of developing type 2 diabetes and obesity, currently at epidemic rates in the United States.
- Trial name
- NCT00728377
- Testing
- Physical activity, Heath & Wellness
- Where
- United States
- Volunteers
- 488 people
- Sponsor
- University of Massachusetts, Amherst
Neuropathy, Diabetic, Neuropathy;Peripheral
Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain
The purpose of this clinical study is to determine the effectiveness of the Erchonia® EVRL™, manufactured by Erchonia Corporation (the Company), in providing prescription home use application for temporary relief of diabetic…
- Conditions
- Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
- Trial name
- NCT05291975
- Testing
- Erchonia® EVRL™
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Erchonia Corporation
Pituitary Adenoma
Proton Radiation Therapy for Pituitary Adenoma
The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on pituitary tumors and analyze possible side effects.
- Trial name
- PI01 (NCT00798057)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Florida
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Type 2 Diabetes Treated With Insulin
Control-IQ Technology in Individuals With Type 2 Diabetes
A prospective, multicenter study of 6 weeks of home use of Control-IQ technology in individuals with type 2 diabetes age 18 and older.
- Trial name
- 2IQ (NCT05111301)
- Testing
- Control-IQ technology 1.5
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 2 Diabetes, Hypertension
Step Monitoring to Improve ARTERial Health
Many people with diabetes and/or high blood pressure (hypertension) are not very active. When people are more active, they can reduce the chances of having a heart attack or stroke.
- Trial name
- SMARTER (NCT01475201)
- Testing
- Step count prescription, Usual care
- Where
- 6 sites in Canada
- Volunteers
- 347 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Impaired Fasting Glucose, Impaired Glucose Tolerance
Type 2 Diabetes Mellitus Prevention Ukraine
Development, implementation and evaluation of the effectiveness of lifestyle recommendations for the prevention of type 2 diabetes in rural population of Ukraine
- Conditions
- Impaired Fasting Glucose, Impaired Glucose Tolerance, Type 2 Diabetes
- Trial name
- T2DPUA (NCT04283201)
- Testing
- Physical activity, Macronutrient modification
- Where
- Ukraine
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Komisarenko Institute of Endocrinology and Metobolism
Persistent Organic Pollutants, Endocrine Disrupting Chemicals
Nuts and Olestra for Persistent Organic Pollutant Reduction (NO-POPs) Trial
Persistent organic pollutants (POPs) are mostly fat-soluble halogenated chemicals with very long half-lives. POPs are endocrine disruptors, associated with increased risk for diabetes, alterations in thyroid function, and…
- Conditions
- Persistent Organic Pollutants, Endocrine Disrupting Chemicals, Endocrine Disruptor Effects
- Trial name
- NO-POPs (NCT02675101)
- Testing
- Whole Nuts, Olestra: Fat Free Pringles, Vegetable Oil: Original Pringles
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Diabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients with Type 2 diabetes who are currently taking oral…
- Trial name
- NCT00437112
- Testing
- Human Insulin Inhalation Powder, Insulin Glargine
- Where
- 19 sites in United States, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine
The study will look at the efficacy and safety of NNC0268-0965 (referred to as insulin 965). The study aims to show that insulin 965 has positive effects on the blood vessels.
- Trial name
- NCT04575181
- Testing
- NNC0268-0965, Insulin glargine
- Where
- 2 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and DPP-4 inhibitor in Japanese patients with type 2 diabetes mellitus.
- Trial name
- NCT01242228
- Testing
- ipragliflozin, DPP-4 inhibitor
- Where
- 6 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Astellas Pharma Inc
GHD
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive.
- Trial name
- ESCALATE (NCT06024967)
- Testing
- PEG-somatropin
- Volunteers
- 180 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.